医疗保健 · Healthcare
打开互动页面（K 线、成交价图）Open interactive page →
RPRX · Royalty Pharma plc
内部人交易（Form 4）· Insider trading · 2026-07-01 – 2026-10-22
Royalty Pharma plc（RPRX）内部人交易：2026-07-01 至 2026-10-22，内部人公开市场买入 —、卖出 $20.8M；高管董事有效买入 —、有效卖出 —。最近申报 2026-10-05。
买入 Bought—
卖出 Sold$20.8M
有效买入 Effective bought—
有效卖出 Effective sold—
最近申报 Recent filings
| 交易日 | 内部人 | 类型 | 股数 | 价格 | 金额 | |
|---|---|---|---|---|---|---|
| 2026-10-05 | Urist Marshall EVP, Research & Investments | 卖出 Sell | 4,126 | $57.10 | $236K | SEC |
| 2026-09-28 | Urist Marshall EVP, Research & Investments | 卖出 Sell | 4,126 | $57.88 | $239K | SEC |
| 2026-09-22 | Hite Christopher EVP & Chairman, Partnering | 卖出 Sell | 100,000 | $58.53 | $5.9M | SEC |
| 2026-08-18 | Hite Christopher EVP & Chairman, Partnering | 卖出 Sell | 100,000 | $59.97 | $6.0M | SEC |
| 2026-08-13 | Coyne Terrance P. EVP & CFO | 卖出 Sell | 11,002 | $58.68 | $646K | SEC |
| 2026-06-30 | Hite Christopher EVP & Chairman, Partnering | 卖出 Sell | 130,000 | $56.50 | $7.3M | SEC |
| 2026-07-01 | Urist Marshall EVP, Research & Investments | 卖出 Sell | 9,099 | $55.88 | $508K | SEC |
「有效」= 高管或董事的公开市场主动买卖，排除 10b5-1 计划、行权卖出、缴税卖出、IPO/认购等。
拟出售 Form 144
| 预计出售日 | 申报人 | 股数 | 约金额 | |
|---|---|---|---|---|
| 2026-10-05 | Urist Marshall Officer | 4,126 | $236K | 10b5-1 |
| 2026-09-28 | Urist Marshall Officer | 4,126 | $239K | 10b5-1 |
| 2026-09-22 | SCH Investment Partners LLC Officer | 100,000 | $5.8M | 10b5-1 |
| 2026-08-18 | SCH Investment Partners LLC Officer | 100,000 | $6.0M | 10b5-1 |
| 2026-08-13 | Coyne Terrance P. Officer | 11,002 | $644K | 10b5-1 |
| 2026-08-12 | DESOUZA ERROL B Former Affiliate | 206,352 | $11.9M | |
| 2026-08-12 | DESOUZA ERROL B Former Affiliate | 125,000 | $7.2M | |
| 2026-06-30 | SCH Investment Partners LLC Officer | 100,000 | $5.7M | 10b5-1 |
| 2026-07-01 | Urist Marshall Officer | 9,099 | $508K | 10b5-1 |
内部人 Insiders
Urist Marshall、Hite Christopher、Coyne Terrance P.